Cargando…
晚期非小细胞肺癌抗血管生成药物的联合治疗模式
Treatments for advanced non-small cell lung cancer (NSCLC) include chemotherapy, targeted therapy, and immunotherapy represented by immune checkpoint inhibitors. However, the efficacy of monotherapy is still limited. Nowdays, combination strategy has drawn great attention. Anti-angiogenic agents are...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174111/ https://www.ncbi.nlm.nih.gov/pubmed/34034460 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.16 |